Copay Cards

*Eligible patients pay as little as $10

Terms and Conditions apply

Download Copay Cards
* Eligibility required. Individual savings limited to $970 per tube or $3,880 in maximum total savings per calendar year. Only for use with commercial insurance. If you are enrolled in a state or federally funded prescription insurance program, you may not use the savings card. Terms and Conditions apply

Order Samples

Register or sign in to check availability and request samples.

Order now

Infant Safety Study in patients 3 to <24 months of age

Learn more about a 28-day, single-arm, open-label safety study in 3 to <24 month old patients4

Learn more

“Sometimes I don’t even want to look at my own skin”

Nana is a dancer who has had mild-to-moderate atopic dermatitis for more than 30 years

View Nana's story

Efficacy

EUCRISA has proven efficacy across all pivotal trial primary and secondary endpoints in patients aged 2 years and up1,2

Learn more

Safety Data

Learn more about the safety data of EUCRISA from the 4-week pivotal trials and open-label safety extension study1,3

View safety data

Dosing

EUCRISA can be applied to the skin anywhere on the face and body1
For topical use only. Not for ophthalmic, oral or intravaginal use

Understand more

References

  1. EUCRISA® (crisaborole) Full Prescribing Information. April 2020.
  2. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.e4.
  3. Eichenfield LF, Tom WL, Berger TJ, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1)116-132.
  4. Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to <24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020. 21:275-284.